Loading stock data…
Amneal Pharmaceuticals (AMRX)
$17.23-0.09 (-0.52%)
Market ClosedLast close Jun 26
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Amneal Pharmaceuticals, Inc. in the Healthcare sector is trading at $16.98 with a market capitalization of $5.2B. Wall Street consensus targets $17.25 (4 analysts), implying a +1.6% move over the next 12 months. The stock is currently near its 52-week high of $17.86, remaining 34.8% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $722.52M↓ | $814.32M↑ | $784.51M↑ | $724.51M↑ | $695.42M |
| Gross Profit | $320.11M↑ | $297.19M↑ | $273.97M↓ | $286.25M↑ | $255.89M |
| Operating Income | $148.27M↑ | $114.50M↑ | $70.49M↓ | $112.01M↑ | $100.92M |
| Net Income | $62.26M↑ | $35.08M↑ | $2.37M↓ | $22.42M↑ | $12.20M |
Peer Comparison
JNJUNHPFE
Fundamentals
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internation...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.15B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-268.92%
Volume
Today's trading volume
8.25M
Recent News
1 Mooning Stock Worth Your Attention and 2 We Question
Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.
Korro Bio, Inc. (KRRO) Soars 17.6%: Is Further Upside Left in the Stock?
Korro Bio, Inc. (KRRO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
FDA Seeks Updated Labeling for Testosterone Therapies
The US Food and Drug Administration said Thursday it is requesting updates to prescribing informatio
1 Small-Cap Stock for Long-Term Investors and 2 We Find Risky
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.
Amneal Pharmaceuticals (AMRX) Is Up 17.8% After CREXONT Phase 4 Gains And New Oncology Launch
Earlier this month, Amneal Pharmaceuticals reported positive interim Phase 4 ELEVATE-PD results showing that CREXONT extended-release carbidopa/levodopa capsules improved “Good On” time, reduced “Off” time, and enhanced motor scores in Parkinson’s patients across multiple prior treatment regimens, while maintaining a safety profile consistent with earlier trials and its FDA label. In parallel, Amneal secured FDA approval and 180 days of Competitive Generic Therapy exclusivity for a...